Azacitidine vs Azacitidine (Onureg)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Acute Myeloid Leukemia
Shared mechanism: DNMT1 (DNA methyltransferase 1) · full Acute Myeloid Leukemia pipeline
Azacitidine
Marketed by Bristol-Myers Squibb
NCT00887068 · Phase 3 · completed
This randomized Phase 3 trial assigned 187 patients with AML or MDS in remission after allogeneic stem cell transplant to azacitidine maintenance (93) or no intervention (94). The primary endpoint was relapse-free survival. Median relapse-free survival was 2.07 vs 1.28 years, but the difference was not significant (P=.43), so the primary was missed. Source: the peer-reviewed paper (Oran et al., Blood Adv 2020).
Next expected readout: November 2026 · NCT03850574 (registry estimate)
Reported efficacy
Relapse-free Survival (RFS) (3 years): Relapse-free survival: median 2.07 years with azacitidine maintenance vs 1.28 years with observation (P=.43); multivariate hazard ratio 0.73 (95% CI 0.49 to 1.1; P=.14) (Oran et al., Blood Adv 2020). (missed)
Result source: NCT00887068
Azacitidine (Onureg)
Marketed by Bristol-Myers Squibb
NCT04102020 · Phase 3 · completed
The study was nonrandomized, open-label, sequential, and had no comparator arm; its primary endpoint was dose-limiting toxicity during cycle 1, a safety measure assessed descriptively across dose groups. These design features do not allow a controlled comparison of treatment benefit, so the evidence is limited despite enrollment of 112 participants.
Next expected readout: March 2027 · NCT05287568 (registry estimate)
Reported efficacy
Kaplan-Meier (K-M) Estimate for Overall Survival (OS) (Day 1 (randomization) up to data cut off date of 15 July 2019; median follow-up for OS estimated by the reverse K-M method was 41.2 months for all participants.): QUAZAR AML-001 (n=472), primary endpoint overall survival: median 24.7 months (95% CI 18.7 to 30.5) with oral azacitidine vs 14.8 months (95% CI 11.7 to 17.6) with placebo; HR 0.69 (95% CI 0.55 to 0.86), stratified log-rank p=0.0009 (CT.gov posted results). (met)
Result source: NCT01757535
Results for Acute Myeloid Leukemia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Azacitidine | Azacitidine (Onureg) |
|---|---|---|
| OS, median | 10.4bNCT0107404720 other results
| 24.7 vs 14.8+9.9 vs placeboNCT01757535 |
| Complete remission | 13.3%bNCT039419641 other result
| —Not posted · NCT04173533 |
| Event-free survival, median | 17.7 vs 15.7vs AzacitidineNCT0326895417 other results
| —Not posted · NCT04173533 |
| Duration of response, median | 17.1 vs 18.3vs AzacitidineNCT0326895415 other results
| —Not posted · NCT04173533 |
OS, median
- Azacitidine
- 10.4bNCT01074047
20 other results
- 6.2 NCT03092674
- 5.2 NCT03092674
- 7.4 NCT03092674
- 20.3 vs 16.8 NCT03268954
- 16.1 vs 12.8 NCT03268954
- 30 vs 31.2 NCT00887068
- 7.1 vs 4.1 NCT01358734
- 0.2 vs 4.1 NCT01358734
- 11.6 NCT02719574
- 5.9 NCT02807558
- 8.4 NCT02807558
- 11.7 NCT02807558
- 19.1 NCT01912274
- 20.4 NCT00387647
- 25.2 NCT02719574
- 11.6 NCT02719574
- 10.2 NCT02719574
- 1.2 NCT02719574
- 14 NCT02719574
- 18.7 NCT02719574
- Azacitidine (Onureg)
- 24.7 vs 14.8+9.9 vs placeboNCT01757535
Complete remission
- Azacitidine
- 13.3%bNCT03941964
1 other result
- 26.7% NCT03941964
- Azacitidine (Onureg)
- —Not posted · NCT04173533
Event-free survival, median
- Azacitidine
- 17.7 vs 15.7vs AzacitidineNCT03268954
17 other results
- 14.6 vs 12.8 NCT03268954
- 6.7 NCT01074047
- 3.6 NCT03092674
- 1.8 NCT03092674
- 4.5 NCT03092674
- 7.7 vs 11.2 NCT04266795
- 5.5 NCT02719574
- 3.3 NCT02807558
- 8.3 NCT02807558
- 6.6 NCT02807558
- 18.4 NCT02719574
- 5.7 NCT02719574
- 7.8 NCT02719574
- 4.8 NCT02719574
- 1.1 NCT02719574
- 5.5 NCT02719574
- 8.1 NCT02719574
- Azacitidine (Onureg)
- —Not posted · NCT04173533
Duration of response, median
- Azacitidine
- 17.1 vs 18.3vs AzacitidineNCT03268954
15 other results
- 18.9 vs 18.3 NCT03268954
- 15 vs 8.5 NCT03268954
- 10.4 NCT01074047
- 14.8 NCT02719574
- 5.9 NCT02807558
- 10.8 NCT02807558
- 4.7 NCT02807558
- 11.5 NCT01912274
- 22 NCT02719574
- 3.6 NCT02719574
- 20 NCT02719574
- 7.3 NCT02719574
- 4.7 NCT02719574
- 10.6 NCT02719574
- 20.9 NCT02719574
- Azacitidine (Onureg)
- —Not posted · NCT04173533
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety
Coverage. Azacitidine: 7 of 7 rows · Azacitidine (Onureg): 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Azacitidine Rows use multiple source trials | Azacitidine (Onureg) Rows use multiple source trials |
|---|---|---|
| Overall Survival time to event · months No placebo or comparator arm | 10.4 monthsa,b,c,d NCT01074047 · Phase 3 · registry result, not featured evidence 16 other source trials6.2 months NCT03092674 · Phase 2/3 · registry result, not featured evidence 5.2 months NCT03092674 · Phase 2/3 · registry result, not featured evidence · combination 7.4 months NCT03092674 · Phase 2/3 · registry result, not featured evidence · combination 11.7 months NCT02807558 · Phase 2 · registry result, not featured evidence · combination 8.4 months NCT02807558 · Phase 2 · registry result, not featured evidence · combination 5.9 months NCT02807558 · Phase 2 · registry result, not featured evidence · combination 19.08 months NCT01912274 · Phase 2 · registry result, not featured evidence · combination 20.4 months NCT00387647 · Phase 2 · registry result, not featured evidence 11.6 months NCT02719574 · Phase 1/2 · registry result, not featured evidence NA months NCT02719574 · Phase 1/2 · registry result, not featured evidence 1.2 months NCT02719574 · Phase 1/2 · registry result, not featured evidence 25.2 months NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination 11.6 months NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination 10.2 months NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination 14 months NCT02719574 · Phase 1/2 · registry result, not featured evidence 18.7 months NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination | NA months300 mg Days 1-7e,a,b,c,d NCT01835587 · Phase 1/2 · registry result, not featured evidence show 3 more dosesNA months200 mg Days 1-14 NCT01835587 · Phase 1/2 · registry result, not featured evidence NA months200 mg Days 1-7 NCT01835587 · Phase 1/2 · registry result, not featured evidence NA months150 mg Days 1-14 NCT01835587 · Phase 1/2 · registry result, not featured evidence |
| Relapse-free Survival time to event · months | 25.2 vs 15.6 Standard of Care months*f,g,d NCT00887068 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 · converted to months from 2.1 years as posted | 10.2 vs 4.8 placebo monthsf,g,d NCT01757535 · Phase 3 · combination |
| Relapse-free Survival time to event · months No placebo or comparator arm | 9.3 monthsa,b,c,d NCT01074047 · Phase 3 · registry result, not featured evidence 5 other source trials3.5 months NCT03092674 · Phase 2/3 · registry result, not featured evidence 9.4 months NCT03092674 · Phase 2/3 · registry result, not featured evidence · combination 13.3 months NCT03092674 · Phase 2/3 · registry result, not featured evidence · combination 12.5 months @ 52wk NCT03931291 · Phase 2 · registry result, not featured evidence · combination 18.4 months NCT02719574 · Phase 1/2 · registry result, not featured evidence | 8.38 months*300 mg Days 1-7e,a,b,c,d NCT01835587 · Phase 1/2 · registry result, not featured evidence · converted to months from 255 days as posted show 3 more dosesNA months200 mg Days 1-14 NCT01835587 · Phase 1/2 · registry result, not featured evidence 30.26 months*200 mg Days 1-7 NCT01835587 · Phase 1/2 · registry result, not featured evidence · converted to months from 921 days as posted NA months150 mg Days 1-14 NCT01835587 · Phase 1/2 · registry result, not featured evidence |
| Dropout rate | 6.5%h NCT00887068 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 show 40 more results12.3%20 mg/m^2 + 75 mg/m^2 NCT03268954 · Phase 3 · registry result, not featured evidence · combination 66.7% NCT04842604 · Phase 3 · registry result, not featured evidence · combination 76.7%400 mg + 75 mg NCT03941964 · Phase 3 · registry result, not featured evidence · combination 63.3%400 mg + 20 mg NCT03941964 · Phase 3 · registry result, not featured evidence · combination —Azacitidine NCT01074047 · Phase 3 · registry result, not featured evidence 90%Azacitidine (AZA) NCT01074047 · Phase 3 · registry result, not featured evidence n/a: no completion milestoneAzacitidine NCT03092674 · Phase 2/3 · registry result, not featured evidence n/a: no completion milestoneAzacitidine + Nivolumab NCT03092674 · Phase 2/3 · registry result, not featured evidence · combination —Azacitidine +Midostaurin NCT03092674 · Phase 2/3 · registry result, not featured evidence · combination n/a: no completion milestone20 mg/m^2 + 100/200/400 mg + 75 mg/m^2 NCT04266795 · Phase 2 · registry result, not featured evidence · combination 0% NCT01995578 · Phase 2 · registry result, not featured evidence 88.2%Newly Diagnosed Non-APL AML: Tamib NCT02807558 · Phase 2 · registry result, not featured evidence · combination 92.9%R/R Non-APL AML: Tamibarotene and NCT02807558 · Phase 2 · registry result, not featured evidence · combination 0% NCT03931291 · Phase 2 · registry result, not featured evidence · combination 7.4% NCT01168219 · Phase 2 · registry result, not featured evidence 0% NCT02196857 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneAzacitidine Plus Lenalidomide NCT01358734 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneLenalidomide NCT01358734 · Phase 2 · registry result, not featured evidence 3.2%Vorinostat With Azacitidine, Phase NCT00948064 · Phase 2 · registry result, not featured evidence · combination —Vorinostat With Azacitidine, Phase NCT00948064 · Phase 2 · registry result, not featured evidence · combination 0% NCT01912274 · Phase 2 · registry result, not featured evidence · combination 75% NCT00387647 · Phase 2 · registry result, not featured evidence 0% NCT01083706 · Phase 2 · registry result, not featured evidence —Arm A (Azacitidine) NCT00313586 · Phase 2 · registry result, not featured evidence —Arm B (Azacitidine + Entinostat) NCT00313586 · Phase 2 · registry result, not featured evidence · combination 0% NCT00382590 · Phase 2 · registry result, not featured evidence · combination 0% NCT00326170 · Phase 2 · registry result, not featured evidence · combination —Phase 1: FT-2102 (Single Agent) NCT02719574 · Phase 1/2 · registry result, not featured evidence —Phase 1: FT-2102 + Azacitidine (Co NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2: Cohort 1; FT-2102 (Single NCT02719574 · Phase 1/2 · registry result, not featured evidence —Phase 2: Cohort 2; FT-2102 (Single NCT02719574 · Phase 1/2 · registry result, not featured evidence —Phase 2: Cohort 3; FT-2102 (Single NCT02719574 · Phase 1/2 · registry result, not featured evidence —Phase 2: Cohort 4; FT-2102 + Azaci NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2: Cohort 5; FT-2102 + Azaci NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2: Cohort 6; FT-2102 + Azaci NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2: Cohort 7; FT-2102 (Single NCT02719574 · Phase 1/2 · registry result, not featured evidence —Phase 2: Cohort 8; FT-2102 + Azaci NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone190 mg NCT04629443 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg NCT04629443 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone50 mg NCT04629443 · Phase 1/2 · registry result, not featured evidence · combination | n/a: no completion milestone400 mg + 20 mg/m^2i NCT04102020 · Phase 3 · combination show 9 more resultsn/a: no completion milestone400 mg + 36 mg/m^2 NCT04102020 · Phase 3 · combination n/a: no completion milestone400 mg + 50 mg/m^2 NCT04102020 · Phase 3 · combination n/a: no completion milestone400 mg + 200 mg NCT04102020 · Phase 3 · combination n/a: no completion milestone400 mg + 300 mg NCT04102020 · Phase 3 · combination n/a: no completion milestone NCT01757535 · Phase 3 · combination 100%300 mg Days 1-7 (Cohort 2) NCT01835587 · Phase 1/2 · registry result, not featured evidence 47.4%200 mg Days 1-14 (Cohort 3) NCT01835587 · Phase 1/2 · registry result, not featured evidence 66.7%200 mg Days 1-7 (Cohort 1) NCT01835587 · Phase 1/2 · registry result, not featured evidence 50%150 mg Days 1-14 (Cohort 3A) NCT01835587 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | —h NCT00887068 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 show 40 more results—20 mg/m^2 + 75 mg/m^2 NCT03268954 · Phase 3 · registry result, not featured evidence · combination — NCT04842604 · Phase 3 · registry result, not featured evidence · combination 3.3%400 mg + 75 mg NCT03941964 · Phase 3 · registry result, not featured evidence · combination 26.7%400 mg + 20 mg NCT03941964 · Phase 3 · registry result, not featured evidence · combination —Azacitidine NCT01074047 · Phase 3 · registry result, not featured evidence 36.9%Azacitidine (AZA) NCT01074047 · Phase 3 · registry result, not featured evidence 23.1%Azacitidine NCT03092674 · Phase 2/3 · registry result, not featured evidence 20%Azacitidine + Nivolumab NCT03092674 · Phase 2/3 · registry result, not featured evidence · combination —Azacitidine +Midostaurin NCT03092674 · Phase 2/3 · registry result, not featured evidence · combination 22.9%20 mg/m^2 + 100/200/400 mg + 75 mg/m^2 NCT04266795 · Phase 2 · registry result, not featured evidence · combination — NCT01995578 · Phase 2 · registry result, not featured evidence 0%Newly Diagnosed Non-APL AML: Tamib NCT02807558 · Phase 2 · registry result, not featured evidence · combination 0%R/R Non-APL AML: Tamibarotene and NCT02807558 · Phase 2 · registry result, not featured evidence · combination — NCT03931291 · Phase 2 · registry result, not featured evidence · combination — NCT01168219 · Phase 2 · registry result, not featured evidence — NCT02196857 · Phase 2 · registry result, not featured evidence · combination 17.9%Azacitidine Plus Lenalidomide NCT01358734 · Phase 2 · registry result, not featured evidence · combination 26.7%Lenalidomide NCT01358734 · Phase 2 · registry result, not featured evidence —Vorinostat With Azacitidine, Phase NCT00948064 · Phase 2 · registry result, not featured evidence · combination —Vorinostat With Azacitidine, Phase NCT00948064 · Phase 2 · registry result, not featured evidence · combination — NCT01912274 · Phase 2 · registry result, not featured evidence · combination — NCT00387647 · Phase 2 · registry result, not featured evidence — NCT01083706 · Phase 2 · registry result, not featured evidence —Arm A (Azacitidine) NCT00313586 · Phase 2 · registry result, not featured evidence —Arm B (Azacitidine + Entinostat) NCT00313586 · Phase 2 · registry result, not featured evidence · combination — NCT00382590 · Phase 2 · registry result, not featured evidence · combination — NCT00326170 · Phase 2 · registry result, not featured evidence · combination —Phase 1: FT-2102 (Single Agent) NCT02719574 · Phase 1/2 · registry result, not featured evidence —Phase 1: FT-2102 + Azacitidine (Co NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2: Cohort 1; FT-2102 (Single NCT02719574 · Phase 1/2 · registry result, not featured evidence —Phase 2: Cohort 2; FT-2102 (Single NCT02719574 · Phase 1/2 · registry result, not featured evidence —Phase 2: Cohort 3; FT-2102 (Single NCT02719574 · Phase 1/2 · registry result, not featured evidence —Phase 2: Cohort 4; FT-2102 + Azaci NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2: Cohort 5; FT-2102 + Azaci NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2: Cohort 6; FT-2102 + Azaci NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2: Cohort 7; FT-2102 (Single NCT02719574 · Phase 1/2 · registry result, not featured evidence —Phase 2: Cohort 8; FT-2102 + Azaci NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination 40%190 mg NCT04629443 · Phase 1/2 · registry result, not featured evidence · combination 14.3%100 mg NCT04629443 · Phase 1/2 · registry result, not featured evidence · combination 40%50 mg NCT04629443 · Phase 1/2 · registry result, not featured evidence · combination | 4.3%400 mg + 20 mg/m^2i NCT04102020 · Phase 3 · combination show 9 more results0%400 mg + 36 mg/m^2 NCT04102020 · Phase 3 · combination 0%400 mg + 50 mg/m^2 NCT04102020 · Phase 3 · combination 3.3%400 mg + 200 mg NCT04102020 · Phase 3 · combination 0%400 mg + 300 mg NCT04102020 · Phase 3 · combination 13% NCT01757535 · Phase 3 · combination 0%300 mg Days 1-7 (Cohort 2) NCT01835587 · Phase 1/2 · registry result, not featured evidence 10.5%200 mg Days 1-14 (Cohort 3) NCT01835587 · Phase 1/2 · registry result, not featured evidence 0%200 mg Days 1-7 (Cohort 1) NCT01835587 · Phase 1/2 · registry result, not featured evidence 50%150 mg Days 1-14 (Cohort 3A) NCT01835587 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | 0%h NCT00887068 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 show 40 more results70%20 mg/m^2 + 75 mg/m^2 NCT03268954 · Phase 3 · registry result, not featured evidence · combination 22.2% NCT04842604 · Phase 3 · registry result, not featured evidence · combination 63.3%400 mg + 75 mg NCT03941964 · Phase 3 · registry result, not featured evidence · combination 73.3%400 mg + 20 mg NCT03941964 · Phase 3 · registry result, not featured evidence · combination 79.7%Azacitidine NCT01074047 · Phase 3 · registry result, not featured evidence —Azacitidine (AZA) NCT01074047 · Phase 3 · registry result, not featured evidence 36%Azacitidine NCT03092674 · Phase 2/3 · registry result, not featured evidence 80%Azacitidine + Nivolumab NCT03092674 · Phase 2/3 · registry result, not featured evidence · combination 73.9%Azacitidine +Midostaurin NCT03092674 · Phase 2/3 · registry result, not featured evidence · combination 76.5%20 mg/m^2 + 100/200/400 mg + 75 mg/m^2 NCT04266795 · Phase 2 · registry result, not featured evidence · combination 31.3% NCT01995578 · Phase 2 · registry result, not featured evidence 84.3%Newly Diagnosed Non-APL AML: Tamib NCT02807558 · Phase 2 · registry result, not featured evidence · combination 71.4%R/R Non-APL AML: Tamibarotene and NCT02807558 · Phase 2 · registry result, not featured evidence · combination 39.4% NCT03931291 · Phase 2 · registry result, not featured evidence · combination 33.3% NCT01168219 · Phase 2 · registry result, not featured evidence 87.5% NCT02196857 · Phase 2 · registry result, not featured evidence · combination 76.3%Azacitidine Plus Lenalidomide NCT01358734 · Phase 2 · registry result, not featured evidence · combination 92.9%Lenalidomide NCT01358734 · Phase 2 · registry result, not featured evidence 50%Vorinostat With Azacitidine, Phase NCT00948064 · Phase 2 · registry result, not featured evidence · combination 69.2%Vorinostat With Azacitidine, Phase NCT00948064 · Phase 2 · registry result, not featured evidence · combination 100% NCT01912274 · Phase 2 · registry result, not featured evidence · combination 8.3% NCT00387647 · Phase 2 · registry result, not featured evidence 7.7% NCT01083706 · Phase 2 · registry result, not featured evidence 92.9%Arm A (Azacitidine) NCT00313586 · Phase 2 · registry result, not featured evidence 94.9%Arm B (Azacitidine + Entinostat) NCT00313586 · Phase 2 · registry result, not featured evidence · combination 100% NCT00382590 · Phase 2 · registry result, not featured evidence · combination 91.2% NCT00326170 · Phase 2 · registry result, not featured evidence · combination 62.5%Phase 1: FT-2102 (Single Agent) NCT02719574 · Phase 1/2 · registry result, not featured evidence 76.9%Phase 1: FT-2102 + Azacitidine (Co NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination 75.2%Phase 2: Cohort 1; FT-2102 (Single NCT02719574 · Phase 1/2 · registry result, not featured evidence 33.3%Phase 2: Cohort 2; FT-2102 (Single NCT02719574 · Phase 1/2 · registry result, not featured evidence 80%Phase 2: Cohort 3; FT-2102 (Single NCT02719574 · Phase 1/2 · registry result, not featured evidence 60%Phase 2: Cohort 4; FT-2102 + Azaci NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination 85.7%Phase 2: Cohort 5; FT-2102 + Azaci NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination 65%Phase 2: Cohort 6; FT-2102 + Azaci NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination 80%Phase 2: Cohort 7; FT-2102 (Single NCT02719574 · Phase 1/2 · registry result, not featured evidence 81.8%Phase 2: Cohort 8; FT-2102 + Azaci NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination 80%190 mg NCT04629443 · Phase 1/2 · registry result, not featured evidence · combination 100%100 mg NCT04629443 · Phase 1/2 · registry result, not featured evidence · combination 100%50 mg NCT04629443 · Phase 1/2 · registry result, not featured evidence · combination | 21.7%400 mg + 20 mg/m^2i NCT04102020 · Phase 3 · combination show 9 more results30.4%400 mg + 36 mg/m^2 NCT04102020 · Phase 3 · combination 25%400 mg + 50 mg/m^2 NCT04102020 · Phase 3 · combination 16.7%400 mg + 200 mg NCT04102020 · Phase 3 · combination 18.8%400 mg + 300 mg NCT04102020 · Phase 3 · combination 46.6% NCT01757535 · Phase 3 · combination 75%300 mg Days 1-7 (Cohort 2) NCT01835587 · Phase 1/2 · registry result, not featured evidence 31.6%200 mg Days 1-14 (Cohort 3) NCT01835587 · Phase 1/2 · registry result, not featured evidence 33.3%200 mg Days 1-7 (Cohort 1) NCT01835587 · Phase 1/2 · registry result, not featured evidence 50%150 mg Days 1-14 (Cohort 3A) NCT01835587 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | h poor graft function 33.3% thrombocytopenia 33.3% hepatic 9.2% NCT00887068 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 show 39 more results20 mg/m^2 + 75 mg/m^2 constipation 36.8% anaemia 35% nausea 35% NCT03268954 · Phase 3 · registry result, not featured evidence · combination neutropenia 44.4% (placebo 40%) anaemia 11.1% (placebo 0%) c-reactive protein increased 11.1% (placebo 0%) NCT04842604 · Phase 3 · registry result, not featured evidence · combination 400 mg + 75 mg anaemia 76.7% neutrophil count decreased 63.3% nausea 56.7% NCT03941964 · Phase 3 · registry result, not featured evidence · combination 400 mg + 20 mg anaemia 80% platelet count decreased 53.3% white blood cell count decreased 53.3% NCT03941964 · Phase 3 · registry result, not featured evidence · combination constipation 41.9% nausea 39.4% diarrhoea 36.9% NCT01074047 · Phase 3 · registry result, not featured evidence white blood cell decreased 72% hyponatremia 56% anemia 52% NCT03092674 · Phase 2/3 · registry result, not featured evidence white blood cell decreased 52% anemia 48% anorexia 48% NCT03092674 · Phase 2/3 · registry result, not featured evidence · combination constipation 73.9% fatigue 65.2% white blood cell decreased 65.2% NCT03092674 · Phase 2/3 · registry result, not featured evidence · combination 20 mg/m^2 + 100/200/400 mg + 75 mg/m^2 neutropenia 58% thrombocytopenia 45.7% constipation 42% NCT04266795 · Phase 2 · registry result, not featured evidence · combination nausea 37.5% vomiting 28.1% alanine aminotransferase increased 15.6% NCT01995578 · Phase 2 · registry result, not featured evidence constipation 47.1% decreased appetite 47.1% nausea 47.1% NCT02807558 · Phase 2 · registry result, not featured evidence · combination nausea 50% diarrhoea 39.3% constipation 35.7% NCT02807558 · Phase 2 · registry result, not featured evidence · combination nausea 60.6% platelet count decreased 48.5% vomitting 45.5% NCT03931291 · Phase 2 · registry result, not featured evidence · combination anemia 87.9% neutrophil count decreased 84.8% platelet count decreased 84.8% NCT01168219 · Phase 2 · registry result, not featured evidence diarrhea 25% fatigue 25% febrile neutropenia 25% NCT02196857 · Phase 2 · registry result, not featured evidence · combination constipation 63.2% diarrhoea 50% nausea 50% NCT01358734 · Phase 2 · registry result, not featured evidence · combination fatigue 57.1% constipation 50% hypokalaemia 50% NCT01358734 · Phase 2 · registry result, not featured evidence constipation 23.3% nausea 20% infection 16.7% NCT00948064 · Phase 2 · registry result, not featured evidence · combination fatigue 65.4% nausea 38.5% constipation 32.7% NCT00948064 · Phase 2 · registry result, not featured evidence · combination nausea 48% fatigue 40% thrombocytopenia 38% NCT01912274 · Phase 2 · registry result, not featured evidence · combination platelets - low 79.2% neutrophils/granulocytes (anc/agc) - low 75% leukocytes (total wbc) - low 62.5% NCT00387647 · Phase 2 · registry result, not featured evidence thrombocytopenia 12.8% hypoxia 7.7% anemia 5.1% NCT01083706 · Phase 2 · registry result, not featured evidence hemoglobin 80.8% fatigue 71.7% leukocytes 67.7% NCT00313586 · Phase 2 · registry result, not featured evidence hemoglobin 75.5% fatigue 72.4% leukocytes 58.2% NCT00313586 · Phase 2 · registry result, not featured evidence · combination acute renal failure 25% anemia 25% leukopenia 25% NCT00382590 · Phase 2 · registry result, not featured evidence · combination weakness 14.7% confusion 11.8% somnolence 5.9% NCT00326170 · Phase 2 · registry result, not featured evidence · combination fatigue 37.5% nausea 37.5% diarrhoea 31.3% NCT02719574 · Phase 1/2 · registry result, not featured evidence nausea 66.7% constipation 61.5% platelet count decreased 46.2% NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination nausea 38.6% constipation 26.8% red blood cell count decreased 26.1% NCT02719574 · Phase 1/2 · registry result, not featured evidence fatigue 33.3% headache 33.3% nausea 27.8% NCT02719574 · Phase 1/2 · registry result, not featured evidence hypokalaemia 60% nausea 60% abdominal pain 40% NCT02719574 · Phase 1/2 · registry result, not featured evidence nausea 55% vomiting 50% red blood cell count decreased 35% NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination nausea 42.9% platelet count decreased 42.9% constipation 33.3% NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination constipation 50% nausea 40% fatigue 35% NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination oedema peripheral 50% cough 40% decreased appetite 30% NCT02719574 · Phase 1/2 · registry result, not featured evidence nausea 72.7% constipation 63.6% asthenia 36.4% NCT02719574 · Phase 1/2 · registry result, not featured evidence · combination 190 mg alanine aminotransferase increased 60% aspartate aminotransferase increased 40% diarrhoea 40% NCT04629443 · Phase 1/2 · registry result, not featured evidence · combination 100 mg alanine aminotransferase increased 28.6% aspartate aminotransferase increased 28.6% constipation 28.6% NCT04629443 · Phase 1/2 · registry result, not featured evidence · combination 50 mg alanine aminotransferase increased 80% constipation 80% anaemia 40% NCT04629443 · Phase 1/2 · registry result, not featured evidence · combination | 400 mg + 20 mg/m^2i neutropenia 56.5% thrombocytopenia 34.8% diarrhoea 26.1% NCT04102020 · Phase 3 · combination show 9 more results400 mg + 36 mg/m^2 neutropenia 69.6% thrombocytopenia 56.5% anaemia 34.8% NCT04102020 · Phase 3 · combination nausea 64.8% (placebo 23.2%) vomiting 60.2% (placebo 9.9%) diarrhoea 50.4% (placebo 21.5%) NCT01757535 · Phase 3 · combination 300 mg Days 1-7 (Cohort 2) anaemia 75% abdominal pain 50% decreased appetite 50% NCT01835587 · Phase 1/2 · registry result, not featured evidence 200 mg Days 1-14 (Cohort 3) nausea 63.2% diarrhoea 57.9% anaemia 42.1% NCT01835587 · Phase 1/2 · registry result, not featured evidence 200 mg Days 1-7 (Cohort 1) abdominal pain 66.7% decreased appetite 66.7% diarrhoea 66.7% NCT01835587 · Phase 1/2 · registry result, not featured evidence 150 mg Days 1-14 (Cohort 3A) nausea 100% anaemia 75% blood creatinine increased 75% NCT01835587 · Phase 1/2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 3 versus Phase 1/2.
- bPopulation context differs: registered conditions differ.
- cTreatment context has not been resolved for both arms.
- dThe assessment timepoint is not available for both results.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fPopulation comparability has not been reviewed for both studies.
- gTreatment context differs: monotherapy versus combination.
- hPopulation comparability has not been reviewed for 40 of these studies.
- iPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Azacitidine
show 2 more results
show 2 more results
show 2 more results
+ 62 further endpoints in the CSV export.
Azacitidine (Onureg)
show 3 more results
show 3 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Azacitidine's landscape · Azacitidine (Onureg)'s landscape